{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms at day 28","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.699","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.984","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.239","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 28 vs. Day 56 of treatment for the Armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.089","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.2","value":"41.2"},{"groupId":"OG001","spread":"14.7","value":"40.7"}]}],"title":"Day 1(n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0","value":"42.4"},{"groupId":"OG001","spread":"14.7","value":"40.8"}]}],"title":"Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.3","value":"48.7"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Day 56 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Test to evaluate neurocognitive functions (attention, visual scanning and motor speed). The test consists of a key =9 graphic symbols numbered 1 to 9 and the test =120 graphic symbols to be matched with its number. The test evaluates the number of correct matches within 90 seconds. Higher scores= better performance","dispersionType":"Standard Deviation","groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily.","id":"OG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.","id":"OG001","title":"Placebo-First"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1, Day 28 and Day 56","title":"Symbol Digit Modalities Test Score (SDMT)","type":"PRIMARY","unitOfMeasure":"Number of correct matches"}